212329-37-8 Usage
Description
MRS 1523 is a selective adenosine A3 receptor antagonist with high affinity for human and rat A3 receptors, and significantly lower affinity for rat A1 and A2A receptors. Its ability to selectively target the A3 receptor makes it a valuable tool for studying the role of this receptor in various physiological and pathological processes.
Uses
Used in Pharmaceutical Research:
MRS 1523 is used as a research compound for investigating the role of the A3 adenosine receptor in various signaling pathways. Its high selectivity for the A3 receptor allows researchers to study the receptor's functions in isolation, providing valuable insights into its role in inflammatory, asthmatic, and ischemic responses.
Used in Drug Development:
MRS 1523 is used as a lead compound in the development of new drugs targeting the A3 adenosine receptor. Its selective antagonism of the A3 receptor makes it a promising candidate for the treatment of conditions associated with the receptor's activation, such as inflammatory and asthmatic disorders.
Used in Preclinical Studies:
MRS 1523 is used as a pharmacological tool in preclinical studies to evaluate the therapeutic potential of A3 adenosine receptor antagonists. Its ability to selectively block the A3 receptor allows researchers to assess the efficacy and safety of this class of compounds in animal models of disease.
Used in Clinical Trials:
MRS 1523 may be used as a reference compound in clinical trials to compare the efficacy and safety of new A3 adenosine receptor antagonists. Its well-established pharmacological profile provides a benchmark for evaluating the performance of novel compounds in human subjects.
Biochem/physiol Actions
MRS 1523 is a selective?adenosine A3 receptor antagonist in the rat.
in vitro
mrs1523 reversed the increase in mrna expression in b16-f10 melanoma cells. also, mrs1523 antagonized the modulation in the expression level of the proteins, which indicated that adenosine a3r mediated the responses [1].
in vivo
c57bl/6j, male mice, inoculated b16-f10 melanoma cells, were administered mrs1523 at a dose of 100 μg/kg orally twice daily for 15 days. mrs1523 counteracted the activity of ib-meca which is an adenosine a3r agonist. in addition, it was demonstrated that the response was adenosine a3r mediated. the modulation of up-regulation of gsk-3β expression level was neutralized by mrs1523, further suggesting the specificity of the response [1].
references
[1]. madi, l., rosenberg-haggen, b., nyska, a., & korenstein, r. enhancing pigmentation via activation of a3 adenosine receptors in b16 melanoma cells and in human skin explants. experimental dermatology. 2012; 22(1): 74-77.
Check Digit Verification of cas no
The CAS Registry Mumber 212329-37-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,2,3,2 and 9 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 212329-37:
(8*2)+(7*1)+(6*2)+(5*3)+(4*2)+(3*9)+(2*3)+(1*7)=98
98 % 10 = 8
So 212329-37-8 is a valid CAS Registry Number.
InChI:InChI=1/C23H29NO3S/c1-5-12-17-19(23(26)28-8-4)18(7-3)24-21(16-13-10-9-11-14-16)20(17)22(25)27-15-6-2/h9-11,13-14H,5-8,12,15H2,1-4H3
212329-37-8Relevant articles and documents
A3 adenosine receptor antagonists
-
, (2008/06/13)
Disclosed are pyridine and dihydropyridine derivatives, pharmaceutical compositions comprising one or more of these derivatives, and a method of selectively blocking an A3adenosine receptor of a mammal by the use of one or more of these derivatives. An example of the pyridine derivative is of the formula (I): wherein R2is ethyl, R3is ethylsulfanyl; R4is ethyl, propyl, or hydroxypropyl; R5is ethyl, propyl, fluoroethyl, or fluoropropyl; and R6is phenyl or fluorophenyl. The derivatives of the present invention can be used for inhibiting binding of ligands to an adenosine receptor. The derivatives also can be used for characterizing an adenosine receptor.
